US 11,667,686 B2
Erythropoietin and analogs for veterinary use
Hangjun Zhan, Foster City, CA (US); Lam Nguyen, Union City, CA (US); Yongzhong Li, Burlingame, CA (US); Qingyi Chu, Burlingame, CA (US); Estela Garcia-Murillo, Burlingame, CA (US); Victoria Leitman, Burlingame, CA (US); Stephen Sundlof, Burlingame, CA (US); Richard Chin, San Francisco, CA (US); and Shyr Jiann Li, Millbrae, CA (US)
Assigned to Kindred Biosciences, Inc., Burlingame, CA (US)
Appl. No. 16/617,380
Filed by Kindred Biosciences, Inc., Burlingame, CA (US)
PCT Filed Jun. 5, 2018, PCT No. PCT/US2018/036133
§ 371(c)(1), (2) Date Nov. 26, 2019,
PCT Pub. No. WO2018/226747, PCT Pub. Date Dec. 13, 2018.
Claims priority of provisional application 62/559,104, filed on Sep. 15, 2017.
Claims priority of provisional application 62/516,642, filed on Jun. 7, 2017.
Claims priority of provisional application 62/516,092, filed on Jun. 6, 2017.
Prior Publication US 2021/0032305 A1, Feb. 4, 2021
Int. Cl. C07K 14/505 (2006.01); A61K 47/60 (2017.01); A61K 47/26 (2006.01); A61P 7/06 (2006.01); A61K 38/00 (2006.01)
CPC C07K 14/505 (2013.01) [A61K 47/26 (2013.01); A61K 47/60 (2017.08); A61P 7/06 (2018.01); A61K 38/00 (2013.01)] 10 Claims
 
1. An erythropoietin (EPO) polypeptide comprising the amino acid sequence of SEQ ID NO: 13 except for the presence of at least one N-linked glycosylation site not present in SEQ ID NO: 13, wherein the N-linked glycosylation site consists of the sequence asparagine-xaa-serine or asparagine-xaa-threonine, wherein xaa is any amino acid except proline, and wherein one N-linked glycosylation site does not overlap with another N-linked glycosylation site, and wherein each of the at least one N-linked glycosylation site is present at a position selected from the group consisting of positions 21-23, 29-31, 34-36, 35-37, 53-55, 56-58, 65-67, 66-68, 71-73, 72-74, 73-75, 86-88, 87-89, 111-113, 114-116, 115-117, 116-118, 117-119, 118-120, 119-121, 120-122, 121-123, 122-124, 123-125, 135-137, 136-138, 158-160, and 162-164 of SEQ ID NO: 13.